Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05719
[1]
m6A modification Circ_TET2 Circ_TET2 YTHDC1 : m6A sites Direct Enhancement Non-coding RNA circTET2 HNRNPC  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator YTH domain-containing protein 1 (YTHDC1) READER
m6A Target Circ_TET2
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_TET2 circRNA View Details
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary The mTOR inhibitor dactolisib and FAO inhibitor perhexiline exert a synergistic effect on CLL cells. In addition, the biogenesis of Circ_TET2 can be affected by the splicing process and the RBPs RBMX and YTHDC1. CP028, a splicing inhibitor, modulates the expression of circTET2 and shows pronounced inhibitory effects. m6A-Modified circTET2 Interacting with Heterogeneous nuclear ribonucleoprotein C (HNRNPC) Regulates Fatty Acid Oxidation to Promote the Proliferation of Chronic Lymphocytic Leukemia.
Responsed Disease Chronic lymphocytic leukemia ICD-11: 2A82.0
Responsed Drug CP028
Pathway Response mTOR signaling pathway hsa04150
Cell Process Cell proliferation
In-vitro Model
PBMCs (Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and identified as any blood cell with a round nucleus)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2A82: Leukemogenesis 1 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name AGS-67E Phase 1 [2]
External Link
References
Ref 1 m6A-Modified circTET2 Interacting with HNRNPC Regulates Fatty Acid Oxidation to Promote the Proliferation of Chronic Lymphocytic Leukemia. Adv Sci (Weinh). 2023 Dec;10(34):e2304895. doi: 10.1002/advs.202304895. Epub 2023 Oct 11.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)